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ABSTRACT 
Obesity is a major risk factor for the development of cardiovascular disease. Addressing intra-abdominal adiposity should play a central role in 
future strategies aimed at improving cardiovascular outcomes in patients with abdominal obesity and its associated cardiometabolic risk in 
Sudan. Our research is focusing on a particular gene called R-SPONDIN3, which is play a part in controlling fat distribution, cardiac growth 
through modulation of Wnt (Wnt/β-catenin signaling path way) signaling   R-SPONDIN3 is essential for coronary artery formation in the 
developing heart. It is to find the amount of R-Spondin3 Gene expression in abdominal obesity and Susceptibility to Cardiovascular disease in 
Sudanese Patients in Khartoum State The study was including 300 participants (156 males and 144 females) classified into 3 groups. The first 
group was including 100 participants with abdominal obesity (obese), the second group was including 100 participants already diagnosed with 
CVD entangled with obesity (Heart Group as positive control group), while the third group was include 100 healthy lean volunteers (negative 
control group). All the participants their age group between 27 to 63 years old. BMI and WHR were taken for all subjects too. For detection the 
mutation in RSPO3 gene, Conventional PCR was done for control, obesity and heart subjects respectively and followed by Real Time PCR for all of 
them to measure the amount of gene expression. The findings of this study showed Conventional PCR results were significantly different (P 
<0.001) in Heart group subjects as compared to healthy controls and obese group. Among heart group mutation was detected in some subjects 
(19%) and the rest without mutation (81%) but in obese group no mutation was detected. Comparison between the different studied groups 
according to gene expression showed significant differences (P <0.001) mean value of gene expression in healthy group subjects was 1.0 ± 0.0, 
Obesity group was 2.44 ± 0.50 and heart group subjects was 4.54 ± 0.87 respectively. The amount of R-SPONDIN3 gene expression among the 
obese and CVD patients is show up significant different and the amount of gene expressing among the CVD patients is higher than obese which is 
suggested that the amount of gene expressed in obese patients with heart disease more than obese patients without cardiovascular 
complications   
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INTRODUCTION 
Obesity is defined as a body fat content of more than 20 % in 
average adult males and over 30% in females 1. However 
,obese individuals vary in the amount of excess fat that they 
store ,the regional distribution of that fat within the body 
,and the related health consequences differ noticeable 
amongst these obese persons .It is therefore essential to 
make a distinction between those at augmented risk as a 
result of abdominal obesity from those with general obesity 
.Even though most epidemiological studies have only used 
BMI as a predictor of disease, as assessed by measurement of 
waist circumference or waist – hip ratio , are at a greater risk 
of cardio metabolic risk . 
Abdominal obesity also known as central or visceral obesity 
is one of the essential characteristics of metabolic syndrome. 
There is a strong relationship between visceral fat (android 
obesity phenotype) and cardiovascular disease risk 2. 
Visceral fat is technically excess intra-abdominal adipose 
tissue accumulation. In other words, it’s known as a “deep” 
fat that’s stored further underneath the skin than 
“subcutaneous” belly fat. It’s a form of gel-like fat that’s 
wrapped around major organs, including the liver, pancreas 
and kidneys. 
If you have a protruding belly and large waist, that’s a clear 
sign, you’re storing dangerous visceral fat. While it’s most 
noticeable and pronounced in obese individuals, anyone can 
have visceral fit, many without even knowing it. 
Visceral fat is especially dangerous because, as you’ll find 
out, these fat cells do more than just sit there and cause your 
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pants to feel tight — they also change the way your body 
operates. 3 
Carrying around excess visceral fat is linked with an 
increased risk for Coronary heart disease. 
Visceral fat is considered toxic and spells double-trouble in 
the body because it’s capable of provoking inflammatory 
pathways, plus signaling molecules that can interfere with 
the body’s normal hormonal functions. In fact, it acts almost 
like its very own organ since it’s capable of having such a 
large impact on the body. 4 
Fat cells do more than simply store extra calories — they 
have proved to be much more involved in human physiology 
than we had previously thought. We now know that fat 
tissue itself acts like its own organ by pumping out 
hormones and inflammatory substances. Storing excess fat 
around the organs increases production of pro-inflammatory 
chemicals, also called cytokines, which leads to 
inflammation; at the same time, it interferes with hormones 
that regulate appetite, weight, mood and brain function. 5 
Genetic study is needed for overweight person. Discovery of 
genes associated with obesity are all arguments reinforcing 
the genetic dimension of abdominal obesity. Many studies 
recommended to confirm that R-SPONDIN3 should be 
studied further as a treatment target to manipulate the way 
fat is stored in the body, to help lower cardiovascular risk 6. 
There is also evidence that a high level of cardiorespiratory 
fitness is predictive of a reduced cardiovascular disease 
(CVD) risk, independently from its association with a more 
favorable cardiometabolic risk profile. There is now 
considerable evidence supporting the notion that obesity is a 
heterogeneous condition. Such heterogeneity appears to be 
explained, to a very significant extent, by individual 
differences in regional body fat distribution, particularly in 
visceral adipose tissue accumulation. In addition to visceral 
adiposity as key drivers of the cardiometabolic risk 
associated with overweight/obesity also contribute to the 
risk of various cardiovascular outcomes, and further work 
should clarify their specific functions 7. Studying these 
relationships between mutation of R-SPONDIN3 gene and 
cardiovascular disease lead to lose weight to understand the 
biology underlying body weight regulation and hope that 
these strategies contribute to intervene more efficiently in 
the development of prescription drugs are better able to 
reduce the weight. The researchers found the human gene 
may not affect the overall weight or body mass index, but 
also affects the distribution of fat and reduce or raise the risk 
of cardiovascular disease, suggesting that different types of 
measurements can provide insight into the process of losing 
weight. 
Genetic determinants of total adiposity and distribution 
in women and men: - 
Genome-wide association studies (GWAS) recently have 
identified genetic determinants of common polygenic obesity 
that interact with environmental variables in complex ways, 
but so far explain only a small percentage of the inter-
individual variation in BMI.GWAS and meta-analyses of 
GWAS have also identified novel loci associated with central 
or peripheral fat distribution, some of which are sex-specific. 
Differential mRNA expression is also noted between 
abdominal and gluteal tissue 9. 
R-Spondin 3 (RSPO3) is also called cysteine-rich and single 
thrombospondin domain containing-1 (CRISTIN1), protein 
with TSP type-1 repeat (PWTSR), is a member of the R-
spondin protein family. R-spondins (RSPO) are a recently 
discovered secretory protein family with four members in 
human and mouse. Although all four RSPO proteins activate 
the canonical Wnt pathway, RSPO2 and RSPO3 are more 
potent than RSPO1, whereas RSPO4 is relatively inactive. 
RSPO-3 is expressed ubiquitously and expressed at higher 
level in placenta, small intestine, fetal thymus and lymph 
node. RSPO3 is the activator of the beta-catenin signaling 
cascade, leading to TCF-dependent gene activation. RSPO3 
acts both in the canonical Wnt/beta-catenin-dependent 
pathway and in non-canonical Wnt signaling pathway, 
probably by acting as an inhibitor of ZNRF3, an important 
regulator of the Wnt signaling pathway. RSPO3 also acts as a 
ligand for frizzled FZD8 and LRP6 and may negatively 
regulate the TGF-beta pathway. R-SPONDIN3 play a part in 
controlling fat distribution 10 
MATERIALS AND METHODS 
Study Design: - This was a case control study to find the 
mutation in R-SPONDIN3. The study was carried out during 
the period from August 2016 to March 2019. 
Study area: -The study was conducted in Khartoum State in 
Ahmed Gasim hospital Cardiac Surgery and Renal Transplant 
Center, Alshaab Teaching Hospital and Obesity Centers 
Study Group: -The study was including 300 participants 
(males and females) classified into three groups. The first 
group was include one hundred participants with abdominal 
obesity (obese ), the second group was include one hundred 
participants already diagnosed with CVD entangled with 
obesity (positive control group), while the third group was 
include one hundred healthy lean volunteers (negative 
control group). 
Inclusion Criteria: -Participants with abdominal obesity 
(obese), participants already diagnosed with CVD entangled 
with obesity (positive control group) and hundred lean 
volunteers. 
Exclusion Criteria: -Any history of chronic hypertension, 
kidney disease, liver disease, coagulation disorders. Prior 
informed consent was taken from all. A detailed history was 
taken from all subjects that include age, history of 
hypertension, renal disease, hepatic dysfunction or any other 
acute or chronic illness. Details of drug intake were also 
noted. Blood pressure recording along with a detailed 
physical examination was done.  
Ethical considerations: -This case control study was 
approved by the research committee – College of Medical 
Laboratory Sciences –Shendi University. Informed consent 
was obtained from each participant before taking the 
samples. 
A simple random sample were taken, seven milliliters 
venous blood samples were withdrawn from fasting 
participants and was divided into 2 tubes under aseptic 
conditions using sterile evacuated tubes from each subject as 
follows: 
- Three milliliters venous blood was put into serum separator 
gel (SSG) tube for performing lipid profile.  
- Four milliliters venous blood was put into a sterile ethylene 
di-amine tetra-acetic acid (EDTA) tube. 
Quality controls and managements: Blood was collected 
with care and adequate safety precautions to ensure test 
results were reliable. Quality Assurance (QA) and standard 
Operating System was followed for all biological and clinical 
tests to achieve validity and reliability of test results. 
Methods of BMI estimation: 
It calculates a value indicative of the fat content of the 
body by dividing the weight by the square of height  
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BMI Categories: 
Categories BMI 
Underweight Less than 18.5 
Normal weight 18.5 – 24.9 
Overweight  25 – 29.9 
Obese 30 or higher 
 
Statistical Analysis Statistical Analysis: -Data were fed to 
the computer and analyzed using IBM SPSS software package 
version 20.0. (Armonk, NY: IB was M Corp)Qualitative data 
were described using number and percent. The Kolmogorov-
Smirnov test was used to verify the normality of distribution 
Quantitative data were described using range (minimum and 
maximum), mean, standard deviation and median. 
Significance of the obtained results was judged at the 5% 
level. Chi-square test was used for categorical variables, to 
compare between different groups. Student t-test.was used 
for normally distributed quantitative variables, to compare 
between two studied groups .F-test (ANOVA) was used for 
normally distributed quantitative variables, to compare 
between more than two groups, and Post Hoc test (Tukey) 
(LSD) for pairwise comparisons. Pearson coefficient to 
correlate between two normally distributed quantitative 
variables. Mann Whitney test was used for abnormally 
distributed quantitative variables, to compare between two 
studied groups .Kruskal Wallis test was used for abnormally 
distributed quantitative variables, to compare between more 
than two studied groups, and Post Hoc (Dunn's multiple 
comparisons test) for pairwise comparisons. 
RESULTS 
Comparison between the different studied groups according 
to gene expression showed significant differences (P <0.001) 
mean value of gene expression in healthy group subjects was 
1.0 ± 0.0, Obesity group was 2.44 ± 0.50 and heart group 
subjects was 4.54 ± 0.87 respectively (Table 1) (Figure 1). 
Correlation between gene expression and age in heart and 
obesity group showed weak positive correlation with the r 
value of age in heart group was 0.034 and obesity group was 
0.007 respectively (Table 2).   
Correlation between gene expression and BMI in heart and 
obesity group showed weak Negative correlation with the r 
value of age in heart group was -0.259 and obesity group was 
0.078 respectively (Table 2).  
Correlation between gene expression and WHR in heart and 
obesity group showed weak Negative correlation with the r 
value of age in heart group was -0.064 and obesity was - 
0.145 respectively (Table 2).  
Comparison between gene expression and fat phenotype 
among the heart group showed significant association (P 
<0.001) mean value of gene expression among heart group 
subjects was 5.0 ± 1.05   Visceral fat and  4.15 ± 0.36 
Subcutaneous fat respectively and Comparison between 
gene expression and fat phenotype among the obesity group 
showed insignificant association (P = 0.663) mean value of 
gene expression among obesity group subjects was 2.45 ± 
0.51   Visceral fat , 2.53 ± 0.51 Gluteal Fat and  4.15 ± 0.36 
Subcutaneous fat respectively (Table 3 ) Figure (2) . 
Comparison between gene expression and sex among the 
heart group showed insignificant association (P = 0.926) 
mean value of gene expression among heart group subjects 
was 4.53 ± 0.91 male and 4.55 ± 0.81 female respectively and 
respectively and Comparison between gene expression and 
sex among the obesity group showed insignificant 
association (P = 0.154) mean value of gene expression 
among obesity group subjects was 2.52 ± 0.51 male and 2.38 
± 0.49 female respectively (Table 4) . 
Comparison between the heart and obesity groups according 
to fat phenotypes showed significant differences (P <0.001) 
number 46 and percent 46 % Visceral fat, number 0 and 
percent 0 % Gluteal Fat and number 54 and percent 54 % 
Subcutaneous fat respectively among the heart group and 
number 31 and percent 31 % Visceral fat, number 17 and 
percent 17 % Gluteal Fat and number 52 and percent 52 %   
Subcutaneous fat respectively among the obesity group 
respectively (Table 5). 
Comparison between the different studied groups according 
to sex showed significant differences (P = 0.035) number 54 
and percent 54 % male and number 46 and percent 46 % 
female among control group, number 60 and percent 60 % 
male and number 40 and percent 40 % female among heart 
group and number 42 and percent 42 % male and number 
58 and percent 58 % female among obesity group 
respectively (Table 6). 
Comparison between the different studied groups according 
to age showed significant differences (P <0.001) mean value 
of age in healthy group subjects 40.70 ± 4.81, Obesity group 
was 43.73 ± 8.85 and heart group subjects was 50.61 ± 8.65 
respectively. Comparison between the control and heart 
groups according to age showed significant differences 
(P1<0.001). Comparison between the control and obesity 
groups according to age showed significant differences (P2 = 
0.015). Comparison between the heart and obesity groups 
according to age showed significant differences (P3 = 
<0.001*) (Table 6) . 
Comparison between the different studied groups according 
to BMI showed significant differences (P <0.001) mean value 
of BMI in healthy group subjects 40.70 ± 4.81,Obesity group 
was 43.73 ± 8.85 and heart group subjects was 50.61 ± 8.65 
respectively . Comparison between the control and heart 
groups according to BMI showed significant differences 
(P1<0.001). Comparison between the control and obesity 
groups according to BMI showed significant differences (P2 = 
0.015). Comparison between the heart and obesity groups 
according to BMI showed insignificant differences 
(P3=0.131)(Table 6) . 
Comparison between the different studied groups according 
to WHR showed significant differences (P <0.001) mean 
value of WHR in healthy group subjects 40.70 ± 4.81, Obesity 
group was 43.73 ± 8.85 and heart group subjects was 50.61 ± 
8.65 respectively. Comparison between the control and heart 
groups according to WHR showed significant differences 
(P1<0.001). Comparison between the control and obesity 
groups according to WHR showed significant differences (P2 
= 0.015). Comparison between the heart and obesity groups 
according to WHR showed insignificant differences 
(P3=0.316) (Table 6). 
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Table (1): Comparison between the different studied groups according to gene expression 
Gene expression 
Control group 
(n = 100) 
Heart Group 
(n = 100) 
Obesity group 
(n = 100) 
F P 
    
946.172* <0.001* Mean ± SD. 1.0 ± 0.0 4.54 ± 0.87 2.44 ± 0.50 
    
Sig. bet. Grps p1<0.001*,p2<0.001*,p3<0.001*   
 
  
 
Figure (1): Comparison between the different studied groups according to gene expression 
 
Table (2): Correlation between Gene expression and different parameters in each group 
 
Gene expression 
Heart Group Obesity group 
r p r p 
Age (years) 0.034 0.739 0.007 0.948 
BMI (kg/m2) -0.259 0.009* 0.078 0.441 
WHR -0.064 0.525 -0.145 0.150 
 
 
Table (3): Relation between Fat phenotypes and gene expression in each group 
Gene expression 
Fat phenotypes Test of 
sig. 
p 
Visceral fat Gluteal Fat Subcutaneous fat 
Heart Group (n= 46) (n= 0) (n= 54)   
    
t=5.229* <0.001* Mean ± SD. 5.0 ± 1.05 - 4.15 ± 0.36 
    
Obesity group (n= 31) (n= 17) (n= 52)   
    
F=0.413 0.663 Mean ± SD. 2.45 ± 0.51 2.53 ± 0.51 2.40 ± 0.50 
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Figure (2): Relation between Fat phenotypes and gene expression in each group 
Table (4): Relation between sex and gene expression in each group 
Gene expression 
Sex 
t p 
Male Female 
Heart Group (n = 60) (n = 40)   
   
0.093 0.926 Mean ± SD. 4.53 ± 0.91 4.55 ± 0.81 
   
Obesity group (n = 42) (n = 58)   
   
1.437 0.154 Mean ± SD. 2.52 ± 0.51 2.38 ± 0.49 
   
  
Table (5): Comparison between the different studied groups according to fat phenotypes 
Fat phenotypes 
Heart Group 
(n = 100) 
Obesity group 
(n = 100) 2 P 
No. % No. % 
Visceral fat 46 46.0 31 31.0 
19.960* <0.001* Gluteal Fat 0 0.0 17 17.0 
Subcutaneous fat 54 54.0 52 52.0 
 
  Table (6): Comparison between the different studied groups according to demographics data 
 
Control group 
(n = 100) 
Heart Group 
(n = 100) 
Obesity group 
(n = 100) Test of Sig. p 
 No. % No. % No. % 
Sex         
Male 54 54.0 60 60.0 42 42.0 2= 
6.731* 
0.035* 
Female 46 46.0 40 40.0 58 58.0 
Age (years)      
    
F= 
43.884* 
<0.001* Mean ± SD. 40.70 ± 4.81 50.61 ± 8.65 43.73 ± 8.85 
    
Sig. bet. Grps p1<0.001*,p2=0.015*,p3<0.001*   
BMI (kg/m2)      
    
F= 
373.477* 
<0.001* Mean ± SD. 21.06 ± 1.41 41.01 ± 7.17 39.44 ± 6.75 
    
Sig. bet. Grps p1<0.001*, p2<0.001*, p3=0.131   
WHR      
    
F= 
106.401* 
<0.001* Mean ± SD. 0.84 ± 0.06 1.05 ± 0.16 1.07 ± 0.14 
    
Sig. bet. Grps p1<0.001*, p2<0.001*, p3=0.316   
  
 Alkinain et al                                                                                                           Journal of Drug Delivery & Therapeutics. 2019; 9(2):355-361 
ISSN: 2250-1177                                                                                     [360]                                                                                     CODEN (USA): JDDTAO 
DISCUSSION 
Body fat distribution is a heritable trait that independently 
predicts type 2 diabetes and cardiovascular risk. Genome-
wide association studies (GWAS) meta-analyses have 
identified sexually dimorphic associations, with greater 
effect in women, between loci within RSPO3 (e.g. rs9491696) 
and BMI-adjusted waist-to-hip ratio (WHR). RSPO3 is a LGR4 
receptor ligand and a Wnt/β-catenin signaling agonist. 
The aim of study was to investigate the possible correlation 
between mutation in R-SPONDIN3 gene, abdominal obesity 
and susceptibility to cardiovascular disease. 
The study was including 300 participants (156 males and 
144 females) classified into three groups. The first group was 
including one hundred participants with abdominal obesity 
(obese), the second group was include one hundred 
participants already diagnosed with CVD entangled with 
obesity (Heart Group as positive control group), while the 
third group was include one hundred healthy lean 
volunteers (negative control group). All the participants 
their age group between 27 to 63 years old. BMI and WHR 
were taken for all subjects too. For detection the mutation in 
RSPO3 gene, Conventional PCR was done for control, obesity 
and heart subjects respectively and followed by Real Time 
PCR for all of them. The same of the three groups underwent 
for lipid profile. For measurement of fat distribution in 
clinical practice, waist circumference (WC) and WHR were 
used to determine regional FD. Computerized tomography 
(CT) and whole body MRI scan were used for evaluating the 
adipose tissue which was considered as gold standard for 
that .To measure the visceral and subcutaneous abdominal 
areas in total abdominal area), a CT or MRI scan was taken at 
the level of L4–L5 or the umbilicus. The ratio of visceral to 
subcutaneous adipose tissue has been shown to be strongly 
correlated with RSPO3 gene in obese subjects and heart 
subjects respectively Abdominal sagittal diameter derived 
from CT or MRI images has also been used to determine 
abdominal FD. The CT and MRI were applied in 200 
volunteers,   
The conventional PCR was done to all of the three groups 
which showed clear variation in the mean value of 
conventional PCR (P <0.001) in Heart group subjects as 
compared to healthy controls and obese group. 
Of the 200 cases (obesity &heart) 19 (19%) were positive for 
mutation in RSPO3 gene all of them from heart group and the 
rest of heart group 81 (81%) were negative for mutation as 
well as obesity group all 0 (0 % ) positive for mutation 
(Table 4 -3). This result was leads us to do real time PCR to 
quantify the level of gene expressed. Comparison between 
the different studied groups according to gene expression 
showed clear variation in the mean value of gene expression 
with (P <0.001) in healthy group subjects  was 1.0 ± 0.0 
,Obesity group was 2.44 ± 0.50 and heart group subjects was 
4.54 ± 0.87 respectively  (Table 1) (Figure 1). This result was 
agreed with the finding of finding of N.Y. Loh11. 
In Correlation between gene expression and age in heart and 
obesity group showed weak positive correlation with the r 
value of age in heart group was 0.034 and obesity group was 
0.007 respectively (Table 2).  This result was agreed with 
finding of Dorit Schleinitz12, who was carried   study on heart 
and obesity group respectively. 
Correlation between gene expression and BMI in heart and 
obesity group showed weak Negative correlation with the r 
value of age in heart group was -0.259 and obesity group was 
0.078 respectively (Table 2). This result was agreed with 
finding of Michael M 13. 
Correlation between gene expression and WHR in heart and 
obesity group showed weak Negative correlation with the r 
value of age in heart group was -0.064 and obesity was - 
0.145 respectively (Table 2). This result was agreed with 
Rajiv  G, 14. 
Comparison between gene expression and fat phenotype 
among the heart group showed significant association (P 
<0.001) mean value of gene expression among heart group 
subjects was 5.0 ± 1.05   Visceral fat and  4.15 ± 0.36 
Subcutaneous fat respectively and Comparison between 
gene expression and fat phenotype among the obesity group 
showed insignificant association (P = 0.663) mean value of 
gene expression among obesity group subjects was 2.45 ± 
0.51   Visceral fat , 2.53 ± 0.51 Gluteal Fat and  4.15 ± 0.36 
Subcutaneous fat respectively (Table 3) Figure (2) . This 
result was agreed with finding of Kalypso Karastergiou15. But 
study the obesity was diagnosed according to the Japanese 
obesity criteria by using CT & MRI Technologies.  
In the Comparison between among heart group according to 
sex and gene expression showed insignificant differences (P 
= 0.926) mean value of gene expression among heart group 
subject was 4.53 ± 0.91 male and 4.55 ± 0.81 female. 
Comparison between among obesity group according to sex 
and gene expression showed insignificant differences (P = 
0.154) mean value of gene expression among heart group 
subject was 2.52 ± 0.51 male and 2.38 ± 0.49 female (Table 
4) .This result was agreed with finding of Atzmon, G 16. 
In the Comparison between the heart and obesity groups 
according to fat phenotypes showed significant differences 
(P <0.001) number 46 and percent 46 % Visceral fat, number 
0 and percent 0 % Gluteal Fat and number 54 and percent 54 
% Subcutaneous fat respectively among the heart group and 
number 31 and percent 31 % Visceral fat, number 17 and 
percent 17 % Gluteal Fat and number 52 and percent 52 % 
Subcutaneous fat respectively among the obesity group 
respectively (Table 5). This result was agreed with finding of 
Ian J. Neeland17 and Tobin M. Abraham18. 
In the Comparison between the different studied groups 
according to age showed significant differences (P <0.001) 
mean value of age in healthy group subjects 40.70 ± 
4.81,Obesity group was 43.73 ± 8.85 and heart group 
subjects was 50.61 ± 8.65 respectively . Comparison between 
the control and heart groups according to age showed 
significant differences (P1<0.001). Comparison between the 
control and obesity groups according to age showed 
significant differences (P2 = 0.015). Comparison between the 
heart and obesity groups according to age showed significant 
differences (P3 = <0.001*) (Table 6). This result was agreed 
with finding of Kalypso 15. 
In the Comparison between the different studied groups 
according to BMI showed significant differences (P <0.001) 
mean value of BMI in healthy group subjects 40.70 ± 4.81, 
Obesity group was 43.73 ± 8.85 and heart group subjects 
was 50.61 ± 8.65 respectively . Comparison between the 
control and heart groups according to BMI showed 
significant differences (P1<0.001). Comparison between the 
control and obesity groups according to BMI showed 
significant differences (P2 = 0.015). Comparison between the 
heart and obesity groups according to BMI showed 
insignificant differences (P3=0.131)(Table 6) .  
In the Comparison between the different studied groups 
according to WHR showed significant differences (P <0.001) 
mean value of WHR in healthy group subjects 40.70 ± 
4.81,Obesity group was 43.73 ± 8.85 and heart group 
subjects was 50.61 ± 8.65 respectively . Comparison between 
the control and heart groups according to WHR showed 
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significant differences (P1<0.001). Comparison between the 
control and obesity groups according to WHR showed 
significant differences (P2 = 0.015). Comparison between the 
heart and obesity groups according to WHR showed 
insignificant differences (P3=0.316) (Table 6) . This result 
was agreed with finding of Adamska M 19 who concluded the 
obese and hearts subjects having higher WHR when 
compared with healthy subjects. 
CONCLUSION 
The amount of the R- SPONDIN3 gene expressed cleared 
different between obese and CVD subjects entangled with 
obesity. 
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